# A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines

> **NCT05323461** · PHASE3 · UNKNOWN · sponsor: **Sinocelltech Ltd.** · enrollment: 1800 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** SCTV01C
- **BIOLOGICAL:** SCTV01E
- **BIOLOGICAL:** Sinopharm inactivated COVID-19 vaccine
- **BIOLOGICAL:** Comirnaty

## Key facts

- **NCT ID:** NCT05323461
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-30
- **Primary completion:** 2022-10-28
- **Final completion:** 2023-05-01
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05323461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05323461, "A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05323461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*